Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma

H. Miyagaki, M. Yamasaki, H. Miyata, T. Takahashi, Y. Kurokawa, K. Nakajima, S. Takiguchi, Y. Fujiwara, H. Ishii, F. Tanaka, Masaki Mori, Y. Doki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Recently, PFTK1 was identified as a member of the cyclin-dependent kinase family; however, its expression and clinical significance in oesophageal squamous cell carcinoma (ESCC) have not been evaluated. Methods: PFTK1 expression was initially examined by expression microarray in 77 ESCC patients. Using independent samples of 223 patients, PFTK1 expression was evaluated immunohistochemically to assess the relationship between expression and various clinicopathological parameters. The association between PFTK1 and the response to chemotherapy was also investigated in pretreatment samples of 85 patients who received chemotherapy as first treatment.Results:Significant upregulation of PFTK1 expression was noted in ESCC compared with normal epithelium. PFTK1 expression was positive in 51.6% (115 out of 223) of the tumours, but did not correlate with any clinicopathological parameter. The 5-year overall survival rate was poorer in patients positive for PFTK1 (43.6%) than those with negative expression (66.2%, P<0.001). Uni-and multivariate analyses identified PFTK1 as an independent marker of prognosis (RR=2.428, 95% CI=1.615-3.711, P>0.001). Out of 85 biopsy samples, 40 (47.1%) tumours showed PFTK1-positive expression, and the response rate to chemotherapy was significantly lower than PFTK1-negative tumours (27.9% vs 72.1%, P>0.001). Conclusion: PFTK1 is not only useful as a prognostic marker, but also as a predictor of the response to chemotherapy.

Original languageEnglish
Pages (from-to)947-954
Number of pages8
JournalBritish journal of cancer
Volume106
Issue number5
DOIs
Publication statusPublished - Feb 28 2012

Fingerprint

Drug Therapy
Neoplasms
Cyclin-Dependent Kinases
Up-Regulation
Survival Rate
Epithelium
Biopsy
Esophageal Squamous Cell Carcinoma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Miyagaki, H., Yamasaki, M., Miyata, H., Takahashi, T., Kurokawa, Y., Nakajima, K., ... Doki, Y. (2012). Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. British journal of cancer, 106(5), 947-954. https://doi.org/10.1038/bjc.2012.35

Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. / Miyagaki, H.; Yamasaki, M.; Miyata, H.; Takahashi, T.; Kurokawa, Y.; Nakajima, K.; Takiguchi, S.; Fujiwara, Y.; Ishii, H.; Tanaka, F.; Mori, Masaki; Doki, Y.

In: British journal of cancer, Vol. 106, No. 5, 28.02.2012, p. 947-954.

Research output: Contribution to journalArticle

Miyagaki, H, Yamasaki, M, Miyata, H, Takahashi, T, Kurokawa, Y, Nakajima, K, Takiguchi, S, Fujiwara, Y, Ishii, H, Tanaka, F, Mori, M & Doki, Y 2012, 'Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma', British journal of cancer, vol. 106, no. 5, pp. 947-954. https://doi.org/10.1038/bjc.2012.35
Miyagaki, H. ; Yamasaki, M. ; Miyata, H. ; Takahashi, T. ; Kurokawa, Y. ; Nakajima, K. ; Takiguchi, S. ; Fujiwara, Y. ; Ishii, H. ; Tanaka, F. ; Mori, Masaki ; Doki, Y. / Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma. In: British journal of cancer. 2012 ; Vol. 106, No. 5. pp. 947-954.
@article{6dba4c7d58b546b6b650d45a78675080,
title = "Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma",
abstract = "Background: Recently, PFTK1 was identified as a member of the cyclin-dependent kinase family; however, its expression and clinical significance in oesophageal squamous cell carcinoma (ESCC) have not been evaluated. Methods: PFTK1 expression was initially examined by expression microarray in 77 ESCC patients. Using independent samples of 223 patients, PFTK1 expression was evaluated immunohistochemically to assess the relationship between expression and various clinicopathological parameters. The association between PFTK1 and the response to chemotherapy was also investigated in pretreatment samples of 85 patients who received chemotherapy as first treatment.Results:Significant upregulation of PFTK1 expression was noted in ESCC compared with normal epithelium. PFTK1 expression was positive in 51.6{\%} (115 out of 223) of the tumours, but did not correlate with any clinicopathological parameter. The 5-year overall survival rate was poorer in patients positive for PFTK1 (43.6{\%}) than those with negative expression (66.2{\%}, P<0.001). Uni-and multivariate analyses identified PFTK1 as an independent marker of prognosis (RR=2.428, 95{\%} CI=1.615-3.711, P>0.001). Out of 85 biopsy samples, 40 (47.1{\%}) tumours showed PFTK1-positive expression, and the response rate to chemotherapy was significantly lower than PFTK1-negative tumours (27.9{\%} vs 72.1{\%}, P>0.001). Conclusion: PFTK1 is not only useful as a prognostic marker, but also as a predictor of the response to chemotherapy.",
author = "H. Miyagaki and M. Yamasaki and H. Miyata and T. Takahashi and Y. Kurokawa and K. Nakajima and S. Takiguchi and Y. Fujiwara and H. Ishii and F. Tanaka and Masaki Mori and Y. Doki",
year = "2012",
month = "2",
day = "28",
doi = "10.1038/bjc.2012.35",
language = "English",
volume = "106",
pages = "947--954",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma

AU - Miyagaki, H.

AU - Yamasaki, M.

AU - Miyata, H.

AU - Takahashi, T.

AU - Kurokawa, Y.

AU - Nakajima, K.

AU - Takiguchi, S.

AU - Fujiwara, Y.

AU - Ishii, H.

AU - Tanaka, F.

AU - Mori, Masaki

AU - Doki, Y.

PY - 2012/2/28

Y1 - 2012/2/28

N2 - Background: Recently, PFTK1 was identified as a member of the cyclin-dependent kinase family; however, its expression and clinical significance in oesophageal squamous cell carcinoma (ESCC) have not been evaluated. Methods: PFTK1 expression was initially examined by expression microarray in 77 ESCC patients. Using independent samples of 223 patients, PFTK1 expression was evaluated immunohistochemically to assess the relationship between expression and various clinicopathological parameters. The association between PFTK1 and the response to chemotherapy was also investigated in pretreatment samples of 85 patients who received chemotherapy as first treatment.Results:Significant upregulation of PFTK1 expression was noted in ESCC compared with normal epithelium. PFTK1 expression was positive in 51.6% (115 out of 223) of the tumours, but did not correlate with any clinicopathological parameter. The 5-year overall survival rate was poorer in patients positive for PFTK1 (43.6%) than those with negative expression (66.2%, P<0.001). Uni-and multivariate analyses identified PFTK1 as an independent marker of prognosis (RR=2.428, 95% CI=1.615-3.711, P>0.001). Out of 85 biopsy samples, 40 (47.1%) tumours showed PFTK1-positive expression, and the response rate to chemotherapy was significantly lower than PFTK1-negative tumours (27.9% vs 72.1%, P>0.001). Conclusion: PFTK1 is not only useful as a prognostic marker, but also as a predictor of the response to chemotherapy.

AB - Background: Recently, PFTK1 was identified as a member of the cyclin-dependent kinase family; however, its expression and clinical significance in oesophageal squamous cell carcinoma (ESCC) have not been evaluated. Methods: PFTK1 expression was initially examined by expression microarray in 77 ESCC patients. Using independent samples of 223 patients, PFTK1 expression was evaluated immunohistochemically to assess the relationship between expression and various clinicopathological parameters. The association between PFTK1 and the response to chemotherapy was also investigated in pretreatment samples of 85 patients who received chemotherapy as first treatment.Results:Significant upregulation of PFTK1 expression was noted in ESCC compared with normal epithelium. PFTK1 expression was positive in 51.6% (115 out of 223) of the tumours, but did not correlate with any clinicopathological parameter. The 5-year overall survival rate was poorer in patients positive for PFTK1 (43.6%) than those with negative expression (66.2%, P<0.001). Uni-and multivariate analyses identified PFTK1 as an independent marker of prognosis (RR=2.428, 95% CI=1.615-3.711, P>0.001). Out of 85 biopsy samples, 40 (47.1%) tumours showed PFTK1-positive expression, and the response rate to chemotherapy was significantly lower than PFTK1-negative tumours (27.9% vs 72.1%, P>0.001). Conclusion: PFTK1 is not only useful as a prognostic marker, but also as a predictor of the response to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84862785395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862785395&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.35

DO - 10.1038/bjc.2012.35

M3 - Article

VL - 106

SP - 947

EP - 954

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -